STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study

Coverage, in order

1. 14d ago
   
   first STAT News indie study

   STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study

   Eli Lilly on Wednesday said that its investigational drug was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study, further boosting the competitive profile of its medicine. In the head-to-head study, people on the highest dose of Lilly’s…

2. 14d ago
   Pharmaphorum UK indie study

   Lilly's triple G overpowers Ozempic in diabetes trial

   Lilly's triple G overpowers Ozempic in diabetes trial Phil.Taylor Wed, 28/10/2026 - 11:50

3. 14d ago
   
   STAT Biotech indie study

   STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

   Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got lots of news today to get into. Lilly’s triple-G drug beats Ozempic in head-to-head study Eli Lilly said this morning that its investigational drug…

4. 14d ago
   
   Healio indie randomized trial

   Retatrutide reduces HbA1c, weight more than Ozempic in diabetes

   Once-weekly retatrutide induced greater declines in HbA1c and body weight than Ozempic 2 mg for adults with type 2 diabetes, according to topline results from the phase 3 open-label TRASCEND-T2D-2 trial. As Healio previously reported, the TRANSCEND-T2D-1 trial found that retatrutide (Eli Lilly), a…

5. 14d ago
   
   BioPharma Dive indie study observational

   Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

   The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

6. 14d ago
   
   MedCity News indie study randomized trial

   Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial

   Topline Phase 3 results show Eli Lilly’s retatrutide beat Novo’s Ozempic on measures of blood sugar and weight loss in adults with type 2 diabetes. Retatrutide is a peptide designed to activate three metabolic targets versus just one hit by Ozempic.

7. 14d ago
   
   Everyday Health mainstream study

   Retatrutide Helped People With Diabetes Lose Twice as Much Weight as Ozempic, New Trial Shows

   People Taking Retatrutide Had More Diarrhea and Vomiting Than Those Taking Ozempic Most of retatrutide’s side effects were mild to moderate and usually went away before the end of the trial, per Lilly. Some were more common on the higher dose of retatrutide. Side effects included: Adults taking the…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.